Hydroxy Cmpf

Introduction

Hydroxy CMPF is a metabolite, an organic compound found within the human body that is an intermediate or end product of metabolic processes. Metabolites serve as a dynamic readout of the body’s physiological state, reflecting ongoing biochemical activities^[1]. The scientific field of metabolomics aims to comprehensively measure these endogenous metabolites in biological fluids like serum to gain a deeper understanding of human health and disease^[1].

Biological Basis

As a metabolite, the presence and concentration of hydroxy CMPF are intrinsically linked to various biochemical pathways. Its levels can be influenced by a complex interplay of environmental factors, such as diet and lifestyle, and an individual’s genetic makeup^[1]. Specifically, genetic variants, including single nucleotide polymorphisms (SNPs), can modulate the function of enzymes or transporters responsible for the synthesis, degradation, or movement of metabolites. These genetic influences can consequently alter metabolite homeostasis and impact overall metabolic health^[1].

Clinical Relevance

Variations in metabolite profiles, including compounds like hydroxy CMPF, are increasingly recognized for their critical role in various clinical contexts. Such metabolic markers can provide insights into disease risk and progression for conditions such as cardiovascular disease, metabolic syndrome, and kidney dysfunction. Research has explored genetic associations with a range of important biomarkers, including C-reactive protein (CRP), an indicator of inflammation^[2]; measures of kidney function such as Glomerular Filtration Rate (GFR), urinary albumin excretion (UAE), and cystatin C (cysC) ^[3]; and levels of liver enzymes ^[4], uric acid^[5], and various markers of dyslipidemia ^[6]. By understanding the genetic factors that govern metabolite levels, researchers aim to uncover underlying disease mechanisms and identify novel targets for therapeutic interventions.

Social Importance

The investigation into metabolites and their genetic determinants carries significant social importance. Identifying genetic variants that influence metabolite concentrations, such as those related to hydroxy CMPF, can pave the way for advancements in personalized medicine. This includes developing more accurate diagnostic tools, crafting tailored nutritional recommendations, and designing targeted strategies for the prevention and management of chronic diseases. This field is crucial for improving our understanding of how an individual’s genetic predispositions interact with their environment, thereby contributing to a more predictive and individualized approach to healthcare.

Limitations

Methodological and Statistical Constraints

Genetic association studies, including those for hydroxy cmpf, face inherent methodological and statistical limitations that can influence the interpretation of findings. Many investigations acknowledge their moderate sample sizes, which can limit the statistical power to detect genetic effects of modest magnitude, increasing the susceptibility to false negative findings.^[7] Furthermore, the extensive number of statistical tests performed in genome-wide association studies (GWAS) heightens the risk of false positive associations, especially when findings lack independent replication. ^[7] The process of prioritizing true signals from numerous associations remains a fundamental challenge without external validation. ^[7]

Early GWAS often utilized a subset of all genetic variants, potentially leading to incomplete coverage and the omission of relevant genes or regulatory regions. ^[8] While imputation techniques are employed to infer missing genotypes and bridge these gaps, they rely on reference panels and can introduce minor error rates. ^[9]Additionally, analyses often exclude single nucleotide polymorphisms (SNPs) with low minor allele frequency, thereby limiting the ability to identify rarer variants that might contribute to the genetic architecture of hydroxy cmpf or related phenotypes.^[10] Replication of previously reported associations is crucial for validating discoveries, yet some studies report low replication rates, which can be attributed to false positives in initial findings, differences between study cohorts, or insufficient statistical power in replication cohorts. ^[7]

Generalizability and Phenotype Assessment

A significant limitation in many genetic studies is the restricted generalizability of findings, primarily due to homogenous study populations. A large proportion of cohorts are composed predominantly of individuals of white European ancestry, which means the applicability of discovered genetic associations to other ethnic or racial groups remains uncertain. ^[11] Demographic biases further limit generalizability, as cohorts may be skewed towards specific age ranges, such as middle-aged to elderly participants, potentially introducing survival bias and making findings less applicable to younger populations. ^[7]

The accuracy and consistency of phenotype assessment are critical, and variations in methodology can impact results. Differences in demographic characteristics and laboratory assay techniques across studies can lead to variability in the measured levels of biomarkers and traits. ^[4] In longitudinal research, particularly when traits are averaged over extended periods and assessed with different equipment, misclassification can occur. This averaging strategy might also mask age-dependent genetic effects by assuming a consistent genetic and environmental influence across a wide age span. ^[12]Furthermore, the use of proxy markers for specific phenotypes, such as TSH for thyroid function or cystatin C for kidney function, can be a limitation if these markers do not fully capture the intended biological state or if they also reflect other physiological processes, thereby complicating the interpretation of their associations with genetic variants.^[3]

Unaccounted Genetic and Environmental Influences

Despite the power of GWAS, several genetic and environmental factors may remain unaccounted for, limiting a complete understanding of complex traits. The assumption that genetic and environmental influences on traits remain constant across a wide age range may not be valid, potentially obscuring age-dependent gene effects. This implies that the observed associations might not represent the full spectrum of genetic influences throughout an individual’s lifespan. ^[12] Additionally, a strong focus on multivariable statistical models, while controlling for confounders, can sometimes lead to overlooking important bivariate associations between individual SNPs and phenotypes that might otherwise reveal simpler genetic relationships. ^[3]

Another critical consideration is the potential for sex-specific genetic effects that may be missed. To manage the burden of multiple testing, some studies opt for sex-pooled analyses, which means that SNPs exclusively associated with phenotypes in either females or males may go undetected. ^[8]This approach can limit a comprehensive understanding of how genetic variants differentially impact biological processes between sexes. Ultimately, even with robust genome-wide approaches, significant knowledge gaps persist. The absence of genome-wide significant associations for all phenotypes under study, such as AST levels in some cohorts, indicates that a considerable portion of the heritability for many complex traits remains unexplained. This highlights the ongoing need for larger studies and more refined methodologies to uncover the full genetic architecture of traits like hydroxy cmpf.^[4]

Variants

The genetic variants rs1177442 in the SLC17A1 gene and rs11188161 in the CYP2C8 gene are of interest for their potential roles in metabolism and physiological processes. The SLC17A1gene encodes the sodium-phosphate cotransporter 1 (NPT1), which is primarily involved in the transport of phosphate and organic anions in the kidney, including urate. This transporter plays a critical role in maintaining phosphate homeostasis and in the excretion of various endogenous compounds and xenobiotics, influencing overall metabolic profiles . Variations within genes likeSLC17A1can alter the efficiency of these transport processes, thereby impacting the circulating levels of various metabolites, including those related to hydroxy cmpf, which could be processed or affected by kidney function.

The single nucleotide polymorphism (SNP)rs1177442 in SLC17A1can potentially influence the expression or activity of the NPT1 protein. Changes in NPT1 function due to genetic variations might affect the renal handling of metabolic byproducts or drug metabolites. For instance, altered transporter activity could lead to variations in the plasma concentrations of certain organic compounds, which may include hydroxy cmpf or its precursors.^[1] Such influences on renal transport could also indirectly affect endocrine-related traits and contribute to individual differences in metabolic health.

The CYP2C8 gene, on the other hand, encodes a member of the cytochrome P450 family of enzymes, which are crucial for the metabolism of both endogenous compounds and a wide array of xenobiotics, including many pharmaceuticals. CYP2C8is predominantly expressed in the liver and metabolizes various substrates, notably fatty acids like arachidonic acid and several widely used drugs.^[1] Genetic variations in CYP2C8, such as rs11188161 , can lead to altered enzyme activity, affecting the rate at which these compounds are metabolized and cleared from the body.

The rs11188161 variant in CYP2C8 could result in changes to the enzyme’s efficiency, potentially impacting drug efficacy and toxicity, as well as the metabolism of endogenous substances. For example, modified CYP2C8activity might alter the levels of fatty acid derivatives or other metabolites that are substrates for this enzyme, thereby influencing broader metabolic pathways and contributing to individual variability in metabolic responses. Such changes can be significant in the context of pharmacogenomics and could influence the metabolism of compounds like hydroxy cmpf, depending on their interaction withCYP2C8 pathways. ^[13]

Key Variants

RS ID	Gene	Related Traits
rs1177442	SLC17A1	gout 21-hydroxypregnenolone disulfate measurement 5alpha-pregnan-diol disulfate measurement X-21364 measurement X-12822 measurement
rs11188161	CYP2C8	hydroxy-CMPF measurement

Classification, Definition, and Terminology

Defining Metabolic Traits and Operational Criteria

Metabolic traits represent a broad conceptual framework encompassing various physiological and biochemical characteristics pertinent to metabolic function. ^[14]For a trait such as hydroxy cmpf, its precise definition would align with established understandings of metabolic parameters relevant to overall health and disease risk. Operational definitions within research studies are crucial for consistent data collection and interpretation. In a study involving such traits, measurements are typically obtained under standardized conditions, such as after an overnight fast, with blood samples drawn during a specific morning window (e.g., between 0800 and 1100 h) to minimize diurnal variation.^[14] This rigorous standardization ensures that the collected data, vital for genetic association studies, accurately reflects the trait’s baseline state and minimizes confounding factors.

Measurement Approaches and Key Terminology

The measurement approaches for metabolic traits are highly specific and depend on the biochemical nature of the analyte. For instance, in studies investigating a range of metabolic markers alongside hydroxy cmpf, serum glucose (GLU) might be determined by a glucose dehydrogenase method, while insulin (INS) is often measured via radioimmuno-assay.^[14]Other lipids like total cholesterol (TC), high-density lipoprotein (HDL), and triglycerides (TG) are commonly assessed using enzymatic methods.^[14]Even anthropometric measures, which are also considered metabolic traits, such as height and body weight, adhere to standardized protocols, with body mass index (BMI) calculated as kg m−2.^[14] This diverse terminology and array of precise techniques underscore the multifaceted nature of metabolic health assessment, where each component contributes uniquely to a comprehensive understanding of an individual’s metabolic profile.

Quantitative Classification and Research Focus

Within the context of large-scale genetic analyses, metabolic traits like hydroxy cmpf are predominantly treated as continuous, quantitative variables rather than being assigned to strict categorical disease classifications or severity gradations. This dimensional approach allows for the detection of subtle genetic influences across the full spectrum of a trait, facilitating the identification of genetic variants associated with quantitative changes.^[14] While clinical medicine often employs specific thresholds or cut-off values for diagnosing conditions related to metabolic traits (e.g., for diabetes or dyslipidemia), genetic association studies typically utilize the raw measured values. The primary goal in such research is to uncover novel biological pathways suggested by these quantitative trait loci, providing a foundational understanding that can later inform the development of more refined diagnostic or prognostic criteria.

Biological Background

Metabolic Pathways and Lipid Homeostasis

Metabolomics offers a detailed measurement of endogenous metabolites within body fluids, providing a functional snapshot of an individual’s physiological state. ^[1] These diverse biochemicals, encompassing lipids, carbohydrates, and amino acids, maintain a crucial homeostasis for overall health. Lipid metabolism, in particular, involves intricate pathways for the synthesis, modification, and breakdown of various fat molecules that are essential for cellular integrity and energy storage. For example, the mevalonate pathway, a key route for cholesterol biosynthesis, is critically regulated by the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). ^[15]

The specific composition and regulatory mechanisms of complex lipids, such as plasmalogen/plasmenogen phosphatidylcholines, are vital for membrane structure and numerous cellular functions. ^[1]Proteins like apolipoprotein C-III (APOC3) are central to plasma triglyceride metabolism, significantly shaping the overall lipid profile.^[16] Any dysregulation in these finely tuned metabolic processes can disrupt the balance of crucial metabolites, leading to impaired cellular functions and contributing to a spectrum of health issues.

Genetic Regulation of Metabolic Processes

Genetic mechanisms play a profound role in orchestrating metabolic pathways and influencing the levels of various biomolecules. Genetic variants, such as single nucleotide polymorphisms (SNPs), are recognized for their association with alterations in metabolite homeostasis and predisposition to various diseases.^[1] A notable example involves common SNPs within the HMGCR gene, which have been observed to influence alternative splicing, specifically affecting exon 13. ^[15] This impact on splicing can modulate the enzyme’s activity, subsequently affecting LDL-cholesterol concentrations. ^[15] Alternative splicing is a fundamental gene regulatory process that allows for the production of multiple protein isoforms from a single gene, thereby diversifying protein function and cellular responses. ^[15]

Beyond post-transcriptional modifications, the patterns of gene expression are meticulously controlled by a network of regulatory elements and specific transcription factors. The HNF1A gene encodes hepatocyte nuclear factor-1 alpha, a transcription factor known to regulate the expression of target genes involved in metabolic processes and inflammatory pathways. ^[17] Similarly, the MLXIPLgene encodes a transcription factor that is significantly associated with plasma triglyceride concentrations, demonstrating direct genetic control over lipid metabolism.^[18] These complex genetic controls, including epigenetic modifications, ensure that metabolic pathways are responsive and adaptable to physiological demands.

Biomolecule Function and Cellular Transport

Essential biomolecules are fundamental architects and mediators of complex metabolic and cellular functions. Enzymes, such as HMGCR, are critical catalysts for specific steps in biosynthetic pathways, with structural insights into its catalytic domain revealing mechanisms of activity regulation. ^[15] The assembly state of HMGCR, its oligomerization, also plays a role in determining its degradation rate, adding a layer of control over its cellular abundance. ^[15] Transcription factors, including those encoded by HNF1A and MLXIPL, act as master regulators, governing the transcription of numerous genes to coordinate intricate metabolic programs. ^[17]

Efficient cellular transport mechanisms are indispensable for maintaining metabolite homeostasis and ensuring proper cell function. The SLC2A9gene provides instructions for a facilitative glucose transport protein that notably functions as a urate transporter, significantly influencing serum urate concentration and the excretion of uric acid.^[19] These specialized transporters facilitate the controlled movement of specific metabolites across cellular membranes, which is crucial for their appropriate distribution to target tissues, removal from circulation, or reabsorption, all contributing to systemic metabolic balance.

Systemic Consequences and Pathophysiological Relevance

Disruptions in molecular and cellular metabolic homeostasis can lead to far-reaching systemic consequences, contributing to a range of pathophysiological processes. Genetic variations that influence lipid concentrations, such as those affecting HMGCR or APOC3, are intricately linked to polygenic dyslipidemia and impact an individual’s risk for coronary artery disease.^[9]The regulation of inflammatory biomarkers like C-reactive protein (CRP) by genes such asHNF1A and elements within metabolic syndrome pathways highlights the close interconnections between inflammation and metabolic health. ^[17] Elevated CRP levels are particularly significant due to their established epidemiological association with early diabetogenesis and atherogenesis. ^[17]

At the organ level, specific tissues exhibit unique metabolic roles and differential sensitivities to genetic and environmental influences. For instance, the regulation of uric acid by theSLC2A9transporter primarily affects kidney function and modulates serum urate levels, often with pronounced sex-specific effects, directly impacting susceptibility to conditions like gout.^[19]These systemic and organ-specific metabolic processes are rigorously controlled to maintain overall physiological balance, and their disruption can initiate a cascade of events leading to chronic diseases, thereby underscoring the broad importance of metabolite profiling in understanding human health and disease.^[1]

Pathways and Mechanisms

Metabolic Homeostasis and Flux Control

The maintenance of metabolite levels in the human body is governed by intricate metabolic pathways, where genetic variants can significantly alter the homeostasis of key lipids, carbohydrates, or amino acids. For instance, the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a rate-limiting enzyme in cholesterol biosynthesis, plays a crucial role in regulating the mevalonate pathway. ^[20] Genetic variations in HMGCR can impact LDL-cholesterol levels and influence its catalytic activity, with insights derived from its crystal structure providing details into regulation and catalysis. ^[15] Beyond cholesterol, the biosynthesis of membrane lipids is a fundamental process, and genetic variants in clusters like FADS1 and FADS2 are associated with the fatty acid composition in phospholipids, highlighting genetic influences on diverse lipid components. ^[21]

Carbohydrate and urate metabolism also exhibit complex regulatory mechanisms crucial for systemic balance. The transporterSLC2A9is a newly identified protein that significantly influences serum urate concentration and excretion, playing a role in the pathogenesis of gout.^[19]Furthermore, the glucokinase gene (GCKR) and its mutations, such as those implicated in Maturity-Onset Diabetes of the Young (MODY2), demonstrate how genetic alterations can impact glucose metabolism by affecting the regulatory mechanisms of glucokinase activity.^[22] These examples illustrate how metabolic pathways are tightly regulated, with genetic predispositions influencing metabolite flux and contributing to the overall physiological state.

Signaling Transduction and Receptor Regulation

Cellular functions, including metabolic responses, are critically orchestrated by signaling pathways involving receptor activation and subsequent intracellular cascades. The Mitogen-Activated Protein Kinase (MAPK) pathway, for example, is a fundamental signaling cascade that can be activated by various stimuli, influencing diverse cellular processes. ^[23] Another important regulatory mechanism involves cyclic GMP (cGMP) signaling, which can be antagonized by factors like Angiotensin II that increase the expression of phosphodiesterase 5A (PDE5A) in vascular smooth muscle cells, thereby impacting cardiovascular function.^[24]

Receptor activation also extends to ion channel modulation and cytokine responses. The cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, for instance, exhibits cAMP-dependent chloride transport activity, and its disruption can alter the mechanical properties of smooth muscle cells.^[25] Additionally, genetic variability at the LEPTIN RECEPTOR (LEPR) locus has been identified as a determinant of plasma fibrinogen, highlighting its role in inflammatory and metabolic signaling pathways. ^[26] These pathways underscore the molecular interactions that translate external and internal cues into precise cellular responses.

Gene Expression and Post-Translational Modulations

Regulatory mechanisms, from gene expression to protein modifications, profoundly impact the availability and activity of proteins involved in metabolic and signaling pathways. Gene regulation involves transcription factor binding, as seen with Hepatocyte Nuclear Factor 1 (HNF-1), which can synergistically trans-activate the human C-reactive protein promoter by binding at distinct sites.^[27]Beyond transcriptional control, alternative splicing is a critical post-transcriptional mechanism where common single nucleotide polymorphisms (SNPs) can affect the alternative splicing of exons, such as exon13 ofHMGCR, leading to different protein isoforms with altered functions. ^[15]

Post-translational modifications further fine-tune protein activity and stability. The process of phosphorylation, for example, can regulate protein function, as demonstrated by the phosphorylation of Heat Shock Protein-90 by Thyroid-Stimulating Hormone (TSH) in thyroid cells.^[28] These diverse regulatory layers, from gene-level control through alternative splicing to allosteric and post-translational modifications, ensure that metabolic and signaling components are appropriately activated, deactivated, or processed in response to physiological demands.

Network Crosstalk and Disease Pathogenesis

Biological systems operate through highly interconnected networks where pathways constantly crosstalk, leading to emergent properties that dictate overall physiological function and disease susceptibility. The identification of genetic variants that alter the homeostasis of metabolites provides a functional understanding of the genetics of complex diseases, as these variants can reveal potentially affected pathways.^[1] For example, common variants across multiple loci contribute to polygenic dyslipidemia, indicating complex interactions in lipid metabolism. ^[29]

Dysregulation within these intricate networks is a hallmark of many diseases. The context-dependent genetic effects observed in conditions like hypertension illustrate how genetic predispositions interact with environmental or physiological factors to influence disease manifestation.^[30] Furthermore, studies linking loci to metabolic-syndrome pathways, including LEPR, HNF1A, IL6R, and GCKR, with plasma C-reactive protein, demonstrate how seemingly disparate pathways are integrated at a systems level to contribute to systemic inflammation and disease risk.^[17] A deeper understanding of these network interactions and pathway dysregulation offers crucial insights for identifying therapeutic targets and developing individualized medication strategies for complex human diseases. ^[1]

Clinical Relevance for hydroxy cmpf

Genetic Influence on Inflammatory Biomarkers

Genetic variants play a significant role in determining individual differences in C-reactive protein (CRP) levels, a widely recognized marker of inflammation. Research has identified robust associations between polymorphisms in theHNF1Agene and plasma CRP concentrations. Specifically, studies, such as one performed in the Cardiovascular Health Study (CHS), showed strong evidence of association, with severalHNF1Asingle nucleotide polymorphisms (SNPs) linked to the CRP phenotype, including the common nonsynonymous coding SNP,rs1169288 (Ile27Leu). ^[2] This highlights that HNF1A is among the genes, alongside previously reported CRP and APOE genes, that significantly influence CRP levels. ^[2] Understanding these genetic influences is crucial for dissecting the underlying biological mechanisms that regulate systemic inflammation.

Prognostic Value in Cardiometabolic Diseases

Elevated C-reactive protein levels are known to be prognostically significant, predicting incident stroke, coronary heart disease, and all-cause mortality.^[7] The genetic regulation of CRP, particularly through genes like HNF1Awhich is also linked to metabolic-syndrome pathways, suggests a potential role in the occurrence and progression of complex clinical diseases such as myocardial infarction, stroke, diabetes, and metabolic syndrome.^[2] Epidemiological data further underscore the importance of CRP concentrations in linking to early diabetogenesis and atherogenesis. ^[17] Therefore, genetic variants that influence CRP levels, like those in HNF1A, could serve as markers for an individual’s predisposition to these serious conditions, offering insights into disease pathogenesis long before clinical symptoms appear.

Applications in Risk Assessment and Personalized Medicine

The identification of genetic variants, such as those within the HNF1A gene, that influence circulating inflammatory biomarkers like CRP, holds substantial promise for clinical applications in risk assessment and the advancement of personalized medicine. ^[7]These biomarkers can be utilized to diagnose disease, stratify individuals according to their risk for adverse outcomes, and guide potential interventions.^[7] By incorporating genetic information into monitoring strategies, it may be possible to identify high-risk individuals more precisely, allowing for targeted prevention strategies and tailored treatment selections. Such approaches align with the goal of developing “predictive, preemptive, personalized medicine,” where genetic insights contribute to a more individualized patient care plan and potentially improve long-term health outcomes. ^[7]

References

[1] Gieger, C., et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, p. e1000282.

[2] Reiner AP. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet. 2008;82(5):1195-204.

[3] Hwang, S. J. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Med Genet, vol. 8 Suppl 1, 2007, p. S11. PMID: 17903292.

[4] Yuan, X. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 5, 2008, pp. 520-28. PMID: 18940312.

[5] Dehghan, A. “Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.”Lancet, vol. 372, no. 9654, 2008, pp. 1878-87. PMID: 18834626.

[6] Kathiresan, S. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.”Nat Genet, vol. 40, no. 2, 2008, pp. 189-97. PMID: 18193044.

[7] Benjamin EJ. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet. 2007;8(Suppl 1):S11.

[8] Yang, Q. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, p. S12. PMID: 17903294.

[9] Willer, C. J. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-69. PMID: 18193043.

[10] Pare, G. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genet, vol. 4, no. 7, 2008, p. e1000118. PMID: 18604267.

[11] Melzer, D. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, p. e1000072. PMID: 18464913.

[12] Vasan, R. S. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, p. S2. PMID: 17903301.

[13] Wallace, Cathryn, et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 139-149.

[14] Sabatti, C. et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, vol. 41, no. 1, 2009, pp. 29-37.

[15] Burkhardt, R., et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2008.

[16] Pollin, T.I., et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science, vol. 322, no. 5904, 2008, pp. 1007–1011.

[17] Ridker PM. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet. 2008;82(5):1185-94.

[18] Kooner, Jaspal S., et al. “Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.” Nature Genetics, vol. 40, no. 2, 2008, pp. 149–151.

[19] Vitart, V., et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, vol. 40, 2008, pp. 432–437.

[20] Goldstein, J.L., and M.S. Brown. “Regulation of the mevalonate pathway.” Nature, vol. 343, 1990, pp. 425–430.

[21] Vance, J.E. “Membrane lipid biosynthesis.” Encyclopedia of Life Sciences, 2001.

[22] Garcia-Herrero, C.M., et al. “Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity.”Diabetologia, vol. 50, 2007, pp. 325–333.

[23] J Physiol. “Activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle.”J Physiol, vol. 547, 2003, pp. 977-987.

[24] Lin, C.S., et al. “Expression, distribution and regulation of phosphodiesterase 5.” Curr Pharm Des, vol. 12, 2006, pp. 3439-3457.

[25] Robert, R., et al. “Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells.”J Physiol (Lond), vol. 568, 2005, pp. 483-495.

[26] Zhang, Y.Y., et al. “Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen.”Circ Res, vol. 100, 2007, pp. 917–923.

[27] Toniatti, C., et al. “Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.”EMBO J, vol. 9, 1990, pp. 4467–4475.

[28] Ginsberg, J., et al. “Phosphorylation of Heat Shock Protein-90 by TSH in FRTL-5 Thyroid Cells.” Thyroid, vol. 16, 2006, pp. 737-742.

[29] Kathiresan, S. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65. PMID: 19060906.

[30] Kardia, S.L. “Context-dependent genetic effects in hypertension.”Curr Hypertens Rep, vol. 2, 2000, pp. 32-38.